Literature DB >> 22479293

Melorheostosis and its treatment with intravenous zoledronic acid.

Rosemary Jane Hollick1, Alison Black, David Reid.   

Abstract

We report a case of melorheostosis, a rare bone disorder characterised by mesodermal dysplasia, and its successful and prolonged treatment with the intravenous bisphosphonate zoledronic acid. The middle-aged man presented with pain and swelling of his tibia, which was diagnosed by imaging and bone biopsy as being due to melorheostosis. There was early symptom control after a single infusion of intravenous zoledronic acid. Prolonged symptom relief was accompanied by long-term suppression of the bone resorption marker β cross-laps. We suggest that melorheostosis can be treated with intravenous zoledronic acid and that treatment can be monitored by the use of a specific bone resorption marker.

Entities:  

Year:  2010        PMID: 22479293      PMCID: PMC3047172          DOI: 10.1136/bcr.04.2009.1757

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  A self limiting tumour.

Authors:  S T Quek; A Unger; V N Cassar-Pullicino; S N Roberts
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

Review 2.  MELORHEOSTOSIS. REVIEW OF THE LITERATURE AND REPORT OF AN INTERESTING CASE WITH A NINETEEN-YEAR FOLLOW-UP.

Authors:  J M MORRIS; R L SAMILSON; C L CORLEY
Journal:  J Bone Joint Surg Am       Date:  1963-09       Impact factor: 5.284

3.  [A case of melorheostosis treated with a diphosphonate].

Authors:  R Mora; F Guerreschi; A Fedeli; C Riva
Journal:  Acta Orthop Belg       Date:  1986       Impact factor: 0.500

4.  Advanced imaging of melorheostosis with emphasis on MRI.

Authors:  A M Judkiewicz; M D Murphey; C S Resnik; A H Newberg; H T Temple; W S Smith
Journal:  Skeletal Radiol       Date:  2001-08       Impact factor: 2.199

Review 5.  Case report 843. Malignant fibrous histiocytoma of the femur arising in melorheostosis.

Authors:  S C Baer; A G Ayala; J Y Ro; A W Yasko; A K Raymond; J Edeiken
Journal:  Skeletal Radiol       Date:  1994-05       Impact factor: 2.199

6.  Melorheostosis: a review of 23 cases.

Authors:  J Freyschmidt
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

7.  Increased procollagen alpha1(I) mRNA expression by dermal fibroblasts in melorheostosis.

Authors:  H Endo; A Katsumi; K Kuroda; A Utani; H Moriya; H Shinkai
Journal:  Br J Dermatol       Date:  2003-04       Impact factor: 9.302

8.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

9.  Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

Authors:  Jeanette Wood; Karine Bonjean; Stephan Ruetz; Akeila Bellahcène; Laetitia Devy; Jean Michel Foidart; Vincent Castronovo; Jonathan R Green
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  Melorheostosis and the sclerotomes: a radiological correlation.

Authors:  R O Murray; J McCredie
Journal:  Skeletal Radiol       Date:  1979-06-06       Impact factor: 2.199

View more
  2 in total

Review 1.  Molecular, phenotypic aspects and therapeutic horizons of rare genetic bone disorders.

Authors:  Taha Faruqi; Naveen Dhawan; Jaya Bahl; Vineet Gupta; Shivani Vohra; Khin Tu; Samir M Abdelmagid
Journal:  Biomed Res Int       Date:  2014-10-22       Impact factor: 3.411

2.  Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report.

Authors:  Sarah Byberg; Bo Abrahamsen; Moustapha Kassem; Stuart Ralston; Peter Schwarz
Journal:  J Med Case Rep       Date:  2018-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.